(Q50588093)

16 March 2018

title

Interferon alpha with ribavirin for the treatment of chronic hepatitis C in non-responders or relapsers to interferon monotherapy. (English)

1 reference

16 March 2018

1 reference

1 reference

Moreno-Monteagudo JA

1

1 reference

16 March 2018

Fernández-Bermejo M

2

1 reference

16 March 2018

García-Buey L

3

1 reference

16 March 2018

Sanz P

4

1 reference

16 March 2018

Iacono LO

5

1 reference

16 March 2018

García-Monzón C

6

1 reference

16 March 2018

Borque MJ

7

1 reference

16 March 2018

Moreno-Otero R

8

1 reference

16 March 2018

language of work or name

English

0 references

publication date

1 August 1998

1 reference

16 March 2018

Alimentary Pharmacology & Therapeutics

published in

1 reference

16 March 2018

volume

12

1 reference

16 March 2018

issue

8

1 reference

16 March 2018

page(s)

717-723

1 reference

16 March 2018

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00359.X

21 January 2018

Therapy of Hepatitis C

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00359.X

Eradication of hepatitis C virus RNA after alpha-interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00359.X

Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00359.X

Retreatment with interferon-alpha of chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00359.X

Hepatic stellate (ITO) cells: expanding roles for a liver-specific pericyte

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00359.X

Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00359.X

Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00359.X

Prolonged therapy of chronic hepatitis C with ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00359.X

Effects of ribavirin on intrahepatic and extrahepatic expression of hepatitis C virus in interferon nonresponsive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00359.X

Interferon-ribavirin combination therapy for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00359.X

Frequency and significance of antibodies to histones in autoimmune hepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00359.X

A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00359.X

Interferon for non-A, non-B chronic hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00359.X

10.1046/J.1365-2036.1998.00359.X

21 January 2018

Identifiers

DOI

1 reference

16 March 2018

1 reference

16 March 2018